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Induction of broadly neutralizing antibodies
(bnAbs) that target HIV-1 envelope (Env) is a goal
of HIV-1 vaccine development. A bnAb target
is the Env third variable loop (V3)-glycan site. To
determine whether immunization could induce
antibodies to the V3-glycan bnAb binding site, we
repetitively immunized macaques over a 4-year
period with an Env expressing V3-high mannose
glycans. Env immunizations elicited plasma anti-
bodies that neutralized HIV-1 expressing only
high-mannose glycans—a characteristic shared by
early bnAb B cell lineage members. A rhesus re-
combinant monoclonal antibody from a vaccinated
macaque bound to the V3-glycan site at the same
amino acids as broadly neutralizing antibodies.
A structure of the antibody bound to glycan re-
vealed that the three variable heavy-chain comple-
mentarity-determining regions formed a cavity into
which glycan could insert and neutralized multiple
HIV-1 isolates with high-mannose glycans. Thus,
HIV-1 Env vaccination induced mannose-depen-Cell Rep
This is an open access article under the CC BY-Ndent antibodies with characteristics of V3-glycan
bnAb precursors.INTRODUCTION
Development of an effectiveHIV-1 vaccine is amajor goal ofHIV-1
prevention strategies (Fauci andMarston, 2014).One objective for
anHIV-1vaccine is toelicit broadly reactiveneutralizingantibodies
(bnAbs; Burton et al., 2012; Mascola and Haynes, 2013; Mascola
andMontefiori, 2010). Broad andpotent neutralization ofHIV-1 re-
sults from antibodies binding to virion-associated trimeric enve-
lope (Env) glycoproteins (Corti and Lanzavecchia, 2013; Parren
and Burton, 2001). HIV-1 Env is densely coated with host glycans
that provide both a shield against and a target for immune recog-
nition (Doores, 2015; Leonard et al., 1990; Scanlan et al., 2007a;
Wei et al., 2003). Most gp120 bnAb epitopes include contacts
with glycans (Blattner et al., 2014; Doria-Rose et al., 2014; Garces
et al., 2014; Kong et al., 2013;McLellan et al., 2011; Pancera et al.,
2014; Pejchal et al., 2011; Zhou et al., 2013), yet Env glycans in the
setting of vaccination are poorly immunogenic (Astronomo et al.,
2008, 2010; Doores et al., 2010b; Wang et al., 2008). Recent vac-
cine studies inmonkeys, rabbits, and transgenicmicehave shown
that the presence of glycans alters viral neutralization sensitivity
from potently neutralized to resistant (Bradley et al., 2016; Crooksorts 18, 2175–2188, February 28, 2017 ª 2017 The Author(s). 2175
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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et al., 2015; McCoy et al., 2016; Sanders et al., 2015; Tian et al.,
2016). Thus, recognition of Env glycans is a major hurdle to
HIV-1 vaccine development.
One conservedbroadly neutralizing epitopeonEnv is a patch of
high-mannose glycans surrounding the V3 loop (Kong et al.,
2013). Human monoclonal bnAbs against the V3-glycan Env site
have been isolated from HIV-1-infected individuals, including
PGT121, PGT135, and PGT128, which bind N-linked glycans
near the V3 loop as well as make contacts with adjacent amino
acids (Walker et al., 2011). 2G12 is a neutralizing antibody isolated
from natural infection that binds to Env by contacting only the gly-
cans proximal to the V3 loop (Murin et al., 2014). Glycan-targeted
antibodies are of particular interest because they are among the
most potent bnAbs (Walker et al., 2011) and protect against
chimeric simian-human immunodeficiency virus (SHIV) infection
in macaques at low plasma concentrations (Moldt et al., 2012).
Here we vaccinated rhesus macaques with a group M
consensus Env (M.CON-S gp140CFI) bearing Man9GlcNAc2
high-mannose glycans on the asparagine at 301 (N301) and
the asparagine at 332 (N332) within the V3-glycan site (Go
et al., 2008). We show that Env vaccination induced antibodies
that blocked the binding of the HIV-1 Env glycan-targeting
bnAb 2G12 in ten of ten vaccinated macaques and elicited
plasma neutralizing antibodies for viruses with high-density
Man9GlcNAc2 glycans in six of ten macaques. We report the
isolation of a vaccine-induced recombinant Man9GlcNAc2-
dependent neutralizing antibody B cell clonal lineage (DH501)
that recognized the V3-glycan bnAb epitope and show that
both DH501 and V3-glycan bnAb lineage precursors demon-
strate Man9GlcNAc2-dependent neutralization.
RESULTS
Induction of Glycan bnAb-Blocking Antibodies
V3-glycan bnAbs develop in HIV-1-infected individuals only after
years of infection (Doria-Rose et al., 2009; Gray et al., 2011;
MacLeodet al., 2016;Sather et al., 2009;Simeket al., 2009;Simo-
nich et al., 2016; unpublished data). We asked whether vaccina-
tion over a long duration of time with an Env immunogen with
N301 and N332 high-mannose glycans (Figures S1A and S1B;
Go et al., 2008; Liao et al., 2013b) could elicit glycan-dependentFigure 1. Repetitive Vaccination Elicits Antibodies Targeting the V3-G
(A) CON-S repetitive vaccination regimen. The immunization modality is shown b
(B) Plasma blocking of 2G12 binding to Env. Left: the percent blocking of 2G12 bin
2) or at the end of the vaccination regimen (week 204; Wilcoxon signed-rank test b
antibodies in the plasma of vaccinated macaques. The mean ± SEM of triplicate m
points.
(C) Fluorescence-activated cell sorting (FACS) plots of sorted single B cells fromw
macaque M636 that bind ConC gp120 but not N332A glycan knockout mutant g
(D) Surface plasmon resonance binding to the study immunogen, CON-S gp140
(E) Diagram of the Man9GlcNAc2 glycosylated peptide that recapitulates the PGT
(red N) and Asn332 (red N). The disulfide bond is shown with a straight horizonta
(F) Direct ELISA binding to the V3 base peptide with Man9GlcNAc2 glycans at Asn
V3), or at neither site (blue, aglycone) by vaccine-induced macaque antibody DH
(G) Biolayer interferometry binding of DH501 and its inferred UCA to the peptide
(H) Glycan luminex detection of antibody binding to 16 mM free glycan. The glyc
positive and negative controls, respectively. The complex glycan is Gal2Man3Glc
See also Figures S1 and S2.antibodies. CON-S gp140CFI was chosen for the vaccination
because it is glycosylated at the V3 glycan sites with higher
percentages of high-mannose glycans than other 293 cell line-
derived recombinant Envs such as JR-FL gp140CF (Go et al.,
2008).Wevaccinated ten rhesusmacaqueswithplasmidDNAen-
codingM.CON-S gp145, boostedwith a recombinant adenovirus
serotype 5 viral vector encoding M.CON-S gp145, and further
boosted with gp140CFI protein 15 times over 204 weeks (Fig-
ure 1A; Figure S1C). We examined plasma antibody responses
for their ability to block HIV-1 Env binding of bnAbs 2G12,
PGT125, and PGT128, which are dependent on the N-linked
glycan at N332 for binding (Figure 1B; Figure S1D). Antibodies
that blocked the binding of 2G12 developed in ten of ten animals
byweek204after 15M.CON-Sgp140CFIglycoprotein immuniza-
tions (Figure 1B). PGT125 and PGT128 bnAbs were similarly
blocked by immune plasma (Figure S1D). However, both
PGT125 and PGT128 were blocked by the V3 loop linear peptide
monoclonal antibodies (mAbs) 19B and 447-52D (Figure S1E),
and, thus, the PGT125 and PGT128 plasma blocking assays
were not specific for V3-glycan epitope antibodies. Linear V3
loop antibodies were elicited in the macaques (Figure S1F);
thus, the PGT128 blocking could be convoluted by linear V3
loop antibodies. In contrast, the glycan-binding antibody
2G12 was not blocked by V3 loop mAbs (Figure S1E). Therefore,
plasma blocking of 2G12 binding to Env was a more precise
indicator of glycan-targeted plasma antibody responses than
PGT128 or PGT125. Next, we assessed plasma 2G12 blocking
over the course of immunization in M.CON-S CFI-vaccinated
macaques. DNA priming and rAd5 boost resulted in minimal
2G12 blocking (Figure 1B; Table S1). However, gp140CFI protein
immunizations every 8 to 16 weeks increased 2G12-blocking
activity, and repetitive gp140CFI boosting every 4 weeks further
boosted 2G12 plasma blocking activity (mean peak 2G12
blocking ± SEM = 45% ± 5%, n = 10). Thus, plasma blocking of
2G12 suggested that Env-induced antibodies targeting the
Man9GlcNAc2-dependentV3-glycanbnAbepitopewere induced.
Isolation of a Rhesus Glycan-Reactive Antibody that
Bound the V3-Glycan bnAb Epitope
We next isolated mAbs using antigen-specific memory
B cell sorting with fluorophore-labeled consensus Env gp120lycan bnAb Epitope
elow the line, and the week of vaccination is noted above the line.
ding to B.JR-FL gp140C bymacaque plasma after one DNA vaccination (week
etween weeks 2 and 204, p < 0.05, n = 10). Right: the kinetics of 2G12-blocking
easurements is shown (n = 10). Arrows on the x axis indicate vaccination time
eek 192 peripheral bloodmononuclear cells (PBMCs) from CON-S-immunized
p120.
CFI, by DH501 and the DH501 UCA.
128 epitope. N-linked glycans (green and blue) are shown at positions Asn301
l line.
301 and Asn332 (black, Man9 N332 N301 V3), at Asn301 only (red, Man9 N301
501.
s shown in (E).
an-dependent bnAb PGT128 and peptide-binding antibody 19B were used as
NAc4.
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(Figure 1C). Antibody DH501 was isolated that used the rhesus
IGHV2 family and had a heavy-chain third complementarity-
determining region (CDR-H3) length of 17 amino acids (Table
S2). DH501 bound the vaccine immunogen CON-S gp140CFI
(Figure 1D) as well as Envs from multiple clades (Figure S2). So-
matic mutations were required for binding to CON-S gp140CFI
because the inferred unmutated common ancestor (UCA) of
DH501 did not bind CON-S gp140CFI (Figure 1D; Figure S2).
DH501 binding to M.CON-S gp140CFI was blocked 70% by
2G12 (concentration that inhibits 50% of replication [IC50] =
20 mg/mL; Figure S2B), whereas the peptide-binding V3 anti-
bodies 447-52D and 19B did not block DH501. We determined
the ability of DH501 to bind a synthetic glycopeptide with
Man9GlcNAc2 glycans at N301 and N332 (Man9-V3) that mimics
a portion of the gp120 V3-glycan bnAb site (Figure 1E). Both
PGT128 andDH501 bound the gp120 V3-glycanminimal antigen
(Figures 1F and 1G, top; unpublished data). Like PGT128, DH501
did not bind the aglycone peptide lacking N301 and N332 gly-
cans (Figures 1F and 1G, top). Removal of the glycan at N332
on the glycopeptide and on Env gp120 reduced concentration
at half-maximal response (EC50) binding titers 2-fold and 4-fold
for PGT128 and 2G12, respectively (Figure 1F), but did not affect
DH501 (Figures 1F and 1G, top). Thus, DH501 required the
Man9GlcNAc2 glycan at N301 for binding to the Man9-V3 glyco-
peptide. A key question is what Env form bound the DH501 UCA.
The DH501 UCA bound both Man9-V3 glycopeptides and agly-
cone peptide (Figure 1G, bottom), with strongest binding to the
aglycone. This binding pattern was identical to that of the UCA
of a V3-glycan bnAb B cell lineage, DH270 (unpublished data).
Thus, the DH501 lineage may have been initiated by a denatured
Env form or a peptide fragment (Hangartner et al., 2006; Kuraoka
et al., 2016).
Similar to PGT128,DH501boundstrongly to freeMan9GlcNAc2
(Figure 1H; Figure S2C; Pejchal et al., 2011). Additionally, DH501
bound weakly to Man7GlcNAc2 D1, Man8GlcNAc2 D1D3, and
Man8GlcNAc2 D1D2 (Figure 1H). Conversely, both DH501 and
PGT128 did not bind directly to Gal2Man3GlcNAc4 complex
glycans (Figure 1H). Therefore, terminal mannose residues on
all three glycan arms conferred optimal glycan binding by
DH501 and PGT128. In contrast to the mutated DH501 antibody,
the DH501 UCA did not bind free glycans (Figure 1H; Fig-
ure S2C). Expression of Env in cells capable of only high-
mannose glycosylation (GnTI/ cells; Crispin et al., 2006; Eggink
et al., 2010; Reeves et al., 2002) improved DH501, PGT128, and
2G12 binding but had no effect on control V3 loop peptide
mAb 19B binding (Figure S2D). To express Env with high density
of Man9GlcNAc2 glycans, HIV-1 B.63521 gp140CFI was ex-
pressed in the presence of kifunensine (KIF) a glycosylation
pathway inhibitor that results in Man9GlcNAc2 glycosylation
(Doores and Burton, 2010; Scanlan et al., 2007b). As a positive
control, the binding titer (EC50) of PGT128 to KIF-treated
B.63521 Env (0.002 mg/mL) was improved 40-fold compared
with PGT128 binding to untreated Env (Figure S2E; Pejchal
et al., 2011; Walker et al., 2011). Similar to PGT128, the EC50
of DH501 for KIF-63521 Env improved 24-fold compared
with DH501 binding to untreated Env (Figure S2E). Thus, DH501
binding to Env was augmented when the glycans on Env were
restricted to Man9GlcNAc2.2178 Cell Reports 18, 2175–2188, February 28, 2017DH501 Was Elicited Late during the Vaccination
Regimen
We performed competition ELISAs to determine when, during
vaccination of macaque M636, antibodies targeting the DH501
epitope were elicited. M636 plasma antibody blocking of
DH501 binding to CON-S gp140CFI increased from weeks 156
to 204 of vaccination.
To determine the time of appearance of DH501 clonal lineage
B cells, we performed next-generation sequencing (NGS) of the
heavy-chain variable region (heavy chain variable region [VH])
at the beginning of the protein boosts (week 68), after 4 protein
boosts (week 117), and after 12 protein boosts (week 188; Figures
2A and 2B). After a single protein boost, there were no DH501 VH
sequences detected (Figure 2B), consistent with the lack ofM636
plasma blocking at the same time point (Figures 2A and 2B).
Seven DH501 VH sequences were detected at week 117 after 4
protein boosts. In contrast, 632 sequences were isolated from
duplicate sequencing experiments performed on blood B cells
after 12 protein boosts at vaccination week 188 (Figure 2B).
This late time point corresponded to the time of macaque M636
plasma peak blocking of mAb DH501 binding to Env (Figure 2A).
We clustered the DH501-related sequences to account for the
effect of PCR amplification error in NGS sample preparation and
examined the genealogy of the resulting NGS sequences. The
sequences segregated into two large branches with DH501 ap-
pearing in the branch that was the most genetically distant from
the UCA (Figure 2C). Three sequences from week 117 and one
sequence from week 188 were very similar to the inferred germ-
line antibody of DH501, suggesting that the lineage began at
approximately week 117. BnAbs can be limited by immunologic
tolerance (Haynes and Verkoczy, 2014); therefore, we deter-
mined whether DH501 was autoreactive. DH501 did not bind
to host proteins or DNA antigens, nor did it bind to HIV-unin-
fected HEp-2 cells (Figure S3).
Structural Analysis of Glycan mAb DH501
Wedetermined the structures of the Fab fragment of DH501 in its
unliganded state to 2.8-Å resolution (PDB: 5IIE) and in complex
with a chemically synthesized, biotinylated Man9GlcNAc2 mole-
cule to 2.0 Å (PDB: 5T4Z; Figure 3A; Table S3). Themannose res-
idues bound in a pronounced pocket on the paratope of DH501
(Figure 3B). This pocket was formed and bounded by the three
variable heavy-chain CDRs. Within the VH pocket, DH501 pri-
marily contacted themannose residues with the side-chain func-
tional groups of Asp100E in CDR-H3 and Tyr52 in CDR-H2. Addi-
tional stabilization of the complex was established with contacts
between the mannose residues and the polypeptide backbone
of residues Gly100A and Tyr100C in CDR-H3 as well as through
water H bonds to the Thr100D side chain and the carbonyl of
Gly100A in CDR-H3. Interestingly, the structure indicated that
the most proximal mannose residue had to be a terminal one
on the Man9GlcNAc2 molecule because the electron density
was well defined, and the structure showed no room for another
mannose residue. The electron density for the most distal
mannose residue was not as well defined but best corresponded
with an alpha1-3 linkage, indicating that the mannose residues
were from the D2 arm of the synthesized Man9GlcNAc2
compound.
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Figure 2. Genetic and Plasma Analyses Determine that DH501 Was Elicited after Multiple Protein Boosts
(A) Autologous plasma blocking of DH501 binding to the CON-S immunogen. The plasma from sequential time points frommacaqueM636 fromwhom the DH501
glycan-reactive antibody was isolated was used to block DH501 binding to Env. Time points where next-generation sequencing was performed in (B) are
indicated by black arrows. The red arrow indicates where DH501 was isolated by single B cell sorting and RT-PCR. Values greater than 20% are considered
positive. The mean ± SEM of triplicate measurements is shown (n = 10). Arrows on the x axis indicate vaccination time points.
(B) Comparison of the number of DH501-related sequences after DNA prime, rAd5 boost, and one protein boost, four protein boosts, or 12 protein boosts in
macaque M636, from which DH501 was cloned. Sequencing was performed twice at each time point, and DH501 clonal relatedness was determined using
Clonanalyst (second column). Sequences were clustered to account for sequencing errors. The number of sequence clusters represents the estimated minimum
number of DH501 members at each time point (last column).
(C) The maximum likelihood phylogenetic tree of the 73 total collapsed sequences (72 from NGS and DH501) that are clonally related to DH501. The time point at
which the sequence was observed is indicated by the color code at the bottom.
See also Figure S3.The DH501 Fab structure was compared with known liganded
structures of gp120 V3-glycan antibodies: PGT122 (PDB: 4NCO;
Julien et al., 2013), PGT124 (PDB: 4R2G; Garces et al., 2014),
PGT128 (PDB: 3TYG; Pejchal et al., 2011), and PGT135 (PDB:
4JM2; Kong et al., 2013). In direct contrast to PGT128, which
had long CDR-H2 and -H3 in extended conformations, DH501
had shorter CDRs (Figure 3C). More generally, these shorter
CDRs distinguished DH501 from the broadly neutralizing anti-
bodies PGT128 and PGT135 because they all had heavy-chain
CDR insertions (Walker et al., 2011). Structurally, the long
CDRs with extended conformations were able to penetrate the
glycan shield to contact the gp120 polypeptide (Figures 3D
and 3E; Doores et al., 2015; Kong et al., 2013; Pejchal et al.,
2011; Walker et al., 2011). When DH501 was superimposed
on the structure of PGT122 binding to gp120 or the BG505
SOSIP.664 trimer, it was evident that the 26-amino acid CDR-
H3 of PGT122 made contacts with the Env trimer that DH501
would be less capable of making because of its shorter 17 amino
acid CDR-H3 (Figure 3E). However, despite these differences
in CDR lengths and conformations, the DH501 Fab bound the
near-native, closed BG505 SOSIP.v4.1 trimer (Kd = 0.31 mM; Fig-
ure 3F; de Taeye et al., 2015).
When the electrostatic surface potentials of the paratopes of
DH501 and other V3 glycan antibody structures were compared,DH501 exhibited a large, negatively charged region overlapping
with the glycan-binding pocket (Figure 4). The strong negative
charge in the vicinity of the pocket was due to an Asp54-
Asp55 doublet in CDR-H2 as well as nearby Glu57. Within the
pocket itself, the negative charge was driven by the side chains
of Tyr52 and Asp100E (Figure S4). This charged pocket provided
a favorable environment for interacting with mannose residues in
contrast to the other V3 glycan antibodies that showed broader
surface features and, instead, used their long CDRs to establish
more interfaces with the glycoprotein.
DH501 Neutralization of HIV-1
We produced B.JR-FL, A.BG505, and AE.CNE8 pseudoviruses
in KIF to generate pseudoviruses enriched for a high density
of Man9GlcNAc2 glycosylation (KIF-JRFL, KIF-BG505, and KIF-
CNE8). We found that plasma gamma immunoglobulin (IgG)
from six of ten macaques neutralized at least one KIF-treated
tier 2 virus, whereas none were able to neutralize the corre-
sponding untreated tier 2 pseudoviruses (Figure S5A). However,
the plasma did have relatively high titers of neutralizing
antibodies against untreated, easy-to-neutralize tier 1 pseudovi-
ruses (Figure S5B). We produced seven additional pseudovi-
ruses in KIF-treated cells and tested neutralization by DH501
and its inferred UCA. The DH501 mAb neutralized ten ofCell Reports 18, 2175–2188, February 28, 2017 2179
Figure 3. The Molecular Basis for High-Mannose and Env Recognition by DH501
(A) The structure of DH501 Fv (blue) with the paratope oriented upward. CDR-H3 is highlighted in cyan, CDR-L1 in magenta, and bound constituents of the
Man9GlcNAc2 compound in yellow.
(B) Specific interactions between DH501 (magenta carbons behind a surface rendering) and bound mannose residues (yellow carbons). H-bonding interactions
are shown with dashed lines, and interacting residues on the DH501 heavy chain are labeled.
(C) DH501 Fv (color scheme as in A) superimposed with PGT130 Fv in orange with its CDR-H3 in red and CDR-L1 in green.
(D) DH501 Fv superimposed with the Fvs of V3-glycan broadly neutralizing antibodies in complex with gp120. Gp120 and glycan moieties are shown in gray and
yellow, respectively. DH501 is colored as in (A), and compared antibodies are shown in orange. Long CDRs with extended conformations in V3 glycan bnAbs are
highlighted in red. N-linked Asn residues are numbered for identification of glycans.
(legend continued on next page)
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ten KIF-treated pseudoviruses (geometric mean titer IC50 =
0.34 mg/mL) but none of the untreated pseudoviruses (Figure 5A).
Neutralization activity was acquired with somatic mutation
because the DH501 UCA did not neutralize any of the KIF-
treated or untreated viruses (Figure 5A). As controls, KIF-treated
pseudoviruses were more sensitive to PGT128 neutralization
and more resistant to PG9 (V1V2 bnAb) neutralization than un-
treated pseudoviruses (Figure 5A; Walker et al., 2009, 2011).
Importantly, difficult-to-neutralize (tier 2) viruses remained tier
2 in neutralization sensitivity after KIF treatment (Table S4). Inter-
estingly, KIF-B.MN was the weakest neutralized pseudovirus
and lacked N301, whereas all remaining viruses in the panel
had an asparagine at position 301 (Figure S5C).
DH501 Targets V3 Glycans and the Base of the V3 Loop
for HIV Neutralization
To determine the glycans required for DH501 neutralization, we
eliminated the N-linked glycosylation sites at Env amino acids
295, 301, 332, 386, or 392 in B.JR-FL by mutating asparagine
to alanine at each of these positions. DH501 neutralized all
KIF-JR-FL mutant viruses equivalently, except the N301A
mutant, for which neutralization was abrogated (Figure 5B).
The N301 glycan was also necessary for neutralization of KIF-
JR-FL by PGT128 (Figure 5B), consistent with its interaction
with this glycan in the crystal structure of PGT128 in complex
with the B.JR-FL outer domain (Pejchal et al., 2011). However,
DH501 neutralized KIF-JR-FL N332A, whereas PGT128 showed
a decrease in potency for neutralization of KIF-JR-FL N332A
(Figure 5B). Thus, like Man9-V3 glycopeptide binding (Figures
1F and 1G), DH501 relied only on N301 for neutralization of
KIF-JR-FL.
Most of the V3-glycan bnAbs contact the highly conserved
amino acids Gly324, Asp325, Ile326, and Arg327 (GDIR motif)
at the base of the V3 loop (Garces et al., 2014; Pejchal et al.,
2011; Sok et al., 2016). Mutating Gly324 (ADIR) ablated neutral-
ization of KIF-JRFL by both DH501 and PGT128 (Figure 5C).
Asp325 and Arg327 were required by PGT128 for potent neutral-
ization of KIF-JRFL when mutated singularly (GAIR) or in tandem
(GAIA). These two residues were also required by DH501 for
neutralization when mutated in tandem (Figure 5C). Thus, like
known V3-glycan bnAbs, DH501 neutralization of KIF-treated vi-
ruses was not only N301 glycan-dependent but also relied on
amino acid residues within the GDIR motif of the base of the
V3 loop.
V3 Glycan bnAb Lineage Precursors Require
Man9GlcNAc2 for Heterologous Neutralization
The significance of antibodies that neutralize kifunensine-treated
viruses is a critical question. Thus, we examined the requirement
for Man9GlcNAc2 glycosylation for neutralization susceptibility
during the development of a V3-glycan bnAb lineage, DH270
(Figure 5D; unpublished data). The DH270 bnAb lineage is(E) DH501 Fv (blue) superimposed on PGT122 Fv (orange) bound to the BG505
PGT122s CDR-H3 (red) to deeply penetrate the glycan shield (yellow).
(F) SPR binding of the DH501 Fab to a stabilized BG505 SOSIP.v4.1 trimer. Each
as indicated. The affinity measurements are displayed in the right corner of the g
See also Figure S4.N332 and N301 glycan-dependent and requires the GDIR
motif for binding (unpublished data). The DH270 UCA did not
neutralize either untreated B.JR-FL or KIF-JR-FL (Figure 5D).
Similar to DH501, the first DH270B cell lineage intermediate anti-
body IA4 neutralized KIF-JR-FL (IC50 = 8.73 mg/mL) but not the
untreated B.JR-FL pseudovirus. The intermediate antibodies
IA2 and IA3 neutralized KIF-JR-FL 5-fold and 10-fold more
potently compared with untreated B.JR-FL, respectively. B.JR-
FL neutralization by more mutated DH270 bnAb lineage anti-
bodies was less affected by kifunensine treatment (Figure 5D).
Thus, like DH501, precursors in the V3-glycan bnAb lineage
required a high density of Man9GlcNAc2 for HIV-1 B.JR-FL
neutralization, whereas affinity-matured V3-glycan bnAbs ac-
quired the ability to neutralize B.JR-FL regardless of virus high-
mannose glycan enrichment.
DISCUSSION
Here we have demonstrated that Man9GlcNAc2-dependent Env
antibodies can be induced in the setting of vaccination with Envs
glycosylated with V3 Man9GlcNAc2 glycans. Several groups
have attempted to elicit 2G12-like antibodies using BSA conju-
gated to high-mannose (Astronomo et al., 2008), phage-bearing
high-mannose (Astronomo et al., 2010; Doores et al., 2010b), or
synthetic glycopeptides (Joyce et al., 2008). However, these
studies were unable to produce 2G12-like antibodies, perhaps
because of the domain swap within 2G12 (Calarese et al.,
2003), lack of immunogenicity of host glycans (Scanlan et al.,
2007b), or the lack of high mannose glycosylation on recombi-
nant 293 cell line-produced gp120 and cleavage-deficient non-
SOSIP gp140 immunogens (Bonomelli et al., 2011; Doores
et al., 2010a; Go et al., 2008). In a recent study, one of 15 rabbits
immunized with an Env trimer had a reduction in neutralization
potency when the N332 glycan site was deleted on HIV-1 Env
(Sanders et al., 2015). The rarity of V3-glycan-dependent anti-
bodies elicited by vaccination has raised the question of whether
Env high-mannose glycans are immunogenic (Scanlan et al.,
2007a). Mannose is a component of the cell wall of fungal
pathogens to which the human immune system has evolved
to make antibodies (Deshaw and Pirofski, 1995); however, the
recognition of the precise arrangement of mannose and the ac-
commodation or avoidance of complex glycans on Env may be
an obstacle for eliciting HIV-1 Env glycan antibodies (Garces
et al., 2015). Anti-fungal antibodies have been induced in rabbits
that neutralize HIV-1 produced in kifunensine (Agrawal-Gamse
et al., 2011; Dunlop et al., 2010; Zhang et al., 2015), but whether
these antibodies target bnAb epitopes such as the N332 glycan
or require the GDIR motif is unknown. Furthermore, our study
shows that the significance of kifunensine-dependent neutraliza-
tion is that when V3 glycan bnAb lineages are initiated in HIV-1
infection, bnAb precursors require Man9GlcNAc2 Env glycosyla-
tion for heterologous neutralization and evolve with affinity.6R.SOSIP.664 trimer (gray). DH501’s CDR-H3 (cyan) lacks the length of the
trace represents a different concentration of Fab ranging from 50 to 200 mg/mL
raph.
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Figure 4. DH501 Accommodates High-Mannose Glycan by Forming a Negatively Charged Glycan-Binding Pocket
Shown are paratope surfaces rendered by electrostatic surface potential along with gp120 and labeled glycans in green and yellow, respectively. The elec-
trostatic potential surface renderings were calculated using Chemistry at HarvardMacromolecular Mechanics (CHARMM; Im et al., 1998; Jo et al., 2008a, 2008b)
and expressed in units of kcal/(mol$e). The paratope is shown from a top view, with the heavy chains oriented at the top and light chains at the bottom. CDRs with
extended conformations protruding from the paratope surface are labeled in italics. V3-glycan bnAbs were characterized by one or more long CDRs and an
amphipathic charge distribution. DH501 is distinguished by a pronounced pocket on its paratope bordered and formed almost entirely by the three heavy-chain
CDRs. The mannose residues of Man9GlcNAc2 that bind within the pocket are shown in yellow.maturation to be less dependent on a high density of
Man9GlcNAc2. Structural studies of the PGT121 family have
shown that, as antibodies evolve, they acquire binding mecha-
nisms to avoid or accommodate interfering glycans (Garces
et al., 2015). Although the ability to neutralize KIF-treated
HIV is a trait of early V3-glycan bnAb precursors, it should be
emphasized that not all antibodies like DH501 that neutralize
KIF-treated HIV may have the capacity to affinity-mature to full
bnAb breadth. Thus, the only way to definitively know whether
DH501 is on the path to become an bnAb is to isolate a
DH501-like, affinity-matured bnAb, and work is underway to
seek such antibodies.
The mode of glycan recognition by DH501 is distinct from
bnAbs like PGT121 or PGT128, which use long loops in extended2182 Cell Reports 18, 2175–2188, February 28, 2017conformations to contact glycans (Figure 3). The lack of these
long, extended loops and, instead, the presence of a glycan-
binding pocket is compatible with a scenario in which the glycan
inserts into the cavity, allowing DH501 to move proximal to the
peptide backbone and, thereby, contact the GDIR motif.
How to increase the neutralization breadth of vaccine-induced
antibodies like DH501 is a key question. Superpositions of
DH501 with V3-glycan bnAbs demonstrated that DH501 lacked
the protruding CDR loops created by insertions (Figures 3C and
3D; Figure S4). Insertions and deletions are common in V3-
glycan bnAbs (Walker et al., 2011) but are events rarely found
in the antibody repertoire (Kepler et al., 2014) and may represent
a roadblock to bnAb induction. The removal of the insertion in the
CDR-H2 of PGT128 diminished its neutralization potency and
A
D
B
C
Figure 5. DH501 and Early V3 Glycan bnAb Lineage Antibodies Require Man9GlcNAc2 Glycosylation for Neutralization of HIV-1
(A) Neutralization titers against a cross-clade panel of tier 1 and tier 2 viruses in the TZM-bl assay. Each virus was produced untreated or treated with kifunensine.
PG9 (Man5GlcNAc2-reactive) and PGT128 (Man9GlcNAc2-reactive) were used as controls to demonstrate the modification of envelope glycosylation on virions.
Representative titers are shown from up to four independent assays.
(B) DH501 exhibits N301-dependent neutralization of kifunensine-treated B.JRFL. Shown is neutralization of kifunensine-treated B.JR-FL (KIF-JR-FL) with intact
wild-type N-linked glycosylation sites or with an alanine substitution at the indicated glycosylation site. SVA is a murine leukemia virus used as a negative control
for neutralization. Values are the geometric mean for two independent experiments.
(C) DH501 requires the GDIR motif for neutralization of kifunensine-treated B.JRFL. Shown are TZM-bl neutralization titers (IC50, micrograms per milliliter) for
DH501 and PGT128 against wild-type and GDIR alanine mutant viruses produced in kifunensine-treated cells.
(legend continued on next page)
Cell Reports 18, 2175–2188, February 28, 2017 2183
N332 glycan dependence (Doores et al., 2015; Pejchal et al.,
2011), supporting the notion that insertion and deletions may
be required for optimal neutralization breadth. Future studies
will aim to induce activation induced cytidine deaminase (AID)-
mediated insertions and deletions by vaccinating under condi-
tions that promote AID activity (Bowers et al., 2014). Also,
2G12 did not block 100% of DH501 binding to Env, which could
be due to DH501 requiring the N301 glycan more than the N332
glycan. The N332 glycan is one of the most abundantly targeted
sites on Env for broadly neutralizing antibodies in sera (Walker
et al., 2010). Whether N301 glycan recognition alone is sufficient
to confer broad neutralization is unknown.
To select V3-glycan antibodies that mature during vaccination
into broadly neutralizing antibodies will likely require a sequen-
tial Env vaccination regimen (Bonsignori et al., 2016; Escolano
et al., 2016; Haynes et al., 2012; Liao et al., 2013a; unpublished
data). Synthetic peptides from the base of the V3 loop that
bound to the DH501 UCA (Figure 1G) and the DH270 UCA could
prove useful as germline-targeting immunogens to initiate V3-
glycan bnAb antibodies. This peptide, although it contains a di-
sulfide bond to link the N and C terminus, providing a conforma-
tion similar to the base of the V3 loop, and binds to the UCA,
may not be optimal for induction of conformational Env anti-
bodies unless the disulfide-bonded loop is sufficient for this
purpose. The peptide does not contain the tip of the V3 loop
that is immunogenic for non-neutralizing antibodies but, instead,
includes the base of the V3 loop that contains the GDIR motif
that is bound by many V3-glycan bnAbs (Garces et al., 2014,
2015; Kong et al., 2013). Priming immunizations with the V3
base peptide may be more beneficial than priming with a
gp140 because the UCA of the V3-glycan bnAb DH270 did
not bind to the N332 and N301 glycan-deleted gp140 but did
bind to the aglycone V3 base peptide (unpublished data). This
difference in binding could be due to the V1V2 loop and its gly-
cans shielding the base of the V3 loop in the context of gp140
(Steichen et al., 2016; unpublished data). It will be of interest
to study this peptide in DH270 UCA VH and light chain
variable region (VL) bnAb knockin mice to determine the useful-
ness of the peptide as an immunogen. Subsequent boosts
could include repetitive vaccination with sequential Envs from
HIV-1-infected individuals who develop V3-glycan bnAbs that
have been expressed with only Man9GlcNAc2 because we
show here that the earliest bnAb lineage members require
Man9GlcNAc2 for recognition of the trimer (Escolano et al.,
2016; MacLeod et al., 2016; unpublished data). Additionally,
many bnAbs are limited by immunologic tolerance (Haynes
and Verkoczy, 2014); therefore, relaxing tolerance while vacci-
nating may also be necessary for bnAb induction. Relaxation
of tolerance controls coupled with the types of regimens
described above could shorten the time needed to elicit V3-
glycan antibodies compared with the study described here.(D) Neutralization of B.JR-FL and KIF-JR-FL pseudovirus by the broadly neutrali
shown as IC50 (micrograms per milliliter). The IC50 for B.JR-FL neutralization
Neutralization titers are color coded as >50 (white), 49-1 (light yellow), 0.9–0.1 (ye
two independent experiments.
See also Figure S5.
2184 Cell Reports 18, 2175–2188, February 28, 2017However, immunization occurs yearly with influenza and, thus,
may also be possible for HIV-1 vaccines. Vaccination of infants
and continued boosts throughout life may also be a plausible
method for repetitively vaccinating against HIV-1 in high-risk
populations. Nonetheless, the results presented here demon-
strate that induction of antibodies targeting the V3-glycan
bnAb epitope with an Env expressing Man9GlcNAc2 glycans at
the base of the V3 loop is possible with repetitive immunizations
and represent a first step in the induction of V3-glycan-targeted
neutralizing antibody B cell lineages in primates.
EXPERIMENTAL PROCEDURES
Experimental Design
Indian-origin rhesus macaques (n = 10) were administered CON-S gp145 or
gp140CFI as described in Figure 1A and the Supplemental Experimental Pro-
cedures. Indian-origin rhesus macaques were housed in an Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC)-ac-
credited facility, and all procedures were conducted with Institutional Animal
Care and Use Committee (IACUC) approval.
Oligomannose Bead Immunoassay
Antibody binding to free glycan was measured by a custom glycan luminex
microsphere assay as detailed in the Supplemental Experimental Procedures.
SurfacePlasmonResonanceDetection of AntibodyBinding to gp140
Binding of CON-S gp140CFI (100 mg/mL) or BG505 SOSIP.664.v4.1 gp140
(228 nM to 913 nM) was measured by surface plasmon resonance (SPR)
(BIAcoreS200, GE Healthcare) analysis following capture of each mAb on
anti-human Ig Fc immobilized or direct immobilization of Fabs on sensors as
described earlier (Alam et al., 2013).
Man9GlcNAc2-V3 Glycopeptide and Aglycone Bio-layer
Interferometry
Antibody binding to biotinylated synthetic glycopeptide was measured by bio-
layer interferometry (BLI, ForteBio Octet Red96) analysis.
Direct ELISAs
ELISA plates were coated with antigen, blocked, and incubated with serially
diluted antibodies. Biotinylated antigens were captured with streptavidin.
Bound antibody was detected with anti-human IgG (Rockland) or an anti-rhe-
sus IgG conjugated to horseradish peroxidase (HRP). HRP was detected with
tetramethylbenzidine (TMB) (KPL) and read with a SpectraMax plate reader
(Molecular Devices) and SoftMax Pro v5.3 (Molecular Devices). See also Sup-
plemental Experimental Procedures.
Plasma and Antibody Blocking of N332 Glycan-Dependent bnAb
B.JRFL gp140C-coated plates were incubated sequentially with blocking
plasma or blocking antibody, followed by addition of biotinylated antibodies
of interest. Binding in the presence of competitor was compared with binding
in the absence of the competitor antibodies to determine percent blocking.
See also Supplemental Experimental Procedures.
Epitope-Specific Single B Cell Sorting
B cell sorting was performed as described previously (Wiehe et al., 2014) with
fluorophore-labeled ConC gp120 and ConC N332A gp120 as stated in the
Supplemental Experimental Procedures.zing N332 glycan-dependent DH270 lineage antibodies. Neutralization titer is
is shown in the first column, followed by the KIF-JR-FL neutralization titer.
llow), 0.09–0.023 (orange), and <0.023 (red). Titers are the geometric mean of
Rhesus Immunoglobulin RT-PCR
Immunoglobulin genes were amplified as described previously (Liao et al.,
2009; Wiehe et al., 2014). Contigs of the PCR amplicon sequence were
made, and genes were inferred with the human library in Somatic Diversifica-
tion Analysis software (SoDA) and the rhesus library in Clonanalyst (Volpe et al.,
2006; Wiehe et al., 2014). Unmutated common ancestor antibodies were in-
ferred using the rhesus library in Clonanalyst. Antibodies were expressed as
described in Zhang et al., 2016.
Next-Generation Sequencing of Antibody Genes
Illumina MiSeq sequencing of antibody heavy-chain variable, diversity, joining
(VDJ) sequences was performed on peripheral B cells as described previously
(Zhang et al., 2016). For each time point, sequencing was performed twice on
independent cDNA samples to confirm the absence or presence of antibody
sequences of interest. From single template NGS experiments, we have
observed that the number of errors introduced in PCR amplification in our
NGS sample preparation rarely exceeds four base pairs (<1%). Thus, two se-
quences that each differ by four base pairs (eight total base pair differences)
cannot be reliably determined to derive from two unique B cells. To conserva-
tively account for this, we clustered together sequences with eight or fewer
base pair differences. V, D, and J gene segment inference, clonal relatedness
testing, and reconstruction of clonal lineage trees were performed using the
Clonanalyst software package (Kepler, 2013).
HEp-2 Cell Immunofluorescence
Rhesus antibodies were tested at 25 and 50 mg/mL in the HEp-2 cell immuno-
fluorescence assay (InvernessMedical Professional Diagnostics) as described
previously (Moody et al., 2012).
Recombinant Env Expression
Recombinant Env was produced in 293F cells by transient transfection as
described in the Supplemental Experimental Procedures. BG505 SOSIP.v4.1
trimers were purified using PGT145 affinity chromatography as described pre-
viously (de Taeye et al., 2015).
Glycosylation Analysis
Glycan analysis was performed by liquid chromatography-tandemmass spec-
trometry (LC-MS/MS) as described previously (Go et al., 2013, 2015). See also
Supplemental Experimental Procedures.
In Vitro HIV-1 Neutralization
Neutralizing antibody activity was measured in 96-well culture plates by using
Tat-regulated luciferase (Luc) reporter gene expression to quantify reductions
in virus infection in TZM-bl cells.
Crystallography
Crystallization conditions were tested in a variety of commercially available
screens (QIAGEN, Hampton Research), and crystals of the unliganded Fab
were observed over a reservoir of 0.1MHEPES (pH 6.5), 20%polyethylene gly-
col (PEG) 6000 at a temperature of 20C. Purified DH501 Fab was also mixed
with Man9GlcNAc2-biotin in a 1:3 molar ratio and then treated to the same pro-
cedure as the unliganded Fab. Crystals were observed over a reservoir of 0.2M
CaCl2, 20%PEG3350.Coordinates and structure factors havebeen deposited
in the PDB under accession codes 5IIE (unliganded Fab) and 5T4Z (liganded
Fab). Structural figures were generatedwith Pymol (DeLano, 2012). Further de-
tails can be found in the Supplemental Experimental Procedures.
Statistical Analysis Plan
Descriptive statistics were used to describe immune responses. Neutralization
data were averaged across experiments as geometric means. A Wilcoxon
signed-rank test was performed, including all ten animals, to compare
differences in plasma blocking at two different time points. Statistics were
calculated with SAS v9.4.
ACCESSION NUMBERS
The accession numbers for the coordinates and structure factors for the
DH501 unliganded Fab and the Fab-Man9GlcNAc2 complex reported in thispaper are PDB: 5IIE and 5T4Z. The accession numbers for the sequence of
DH501 heavy and light chain reported in this paper are GenBank: KY490540
andKY490541. The accession numbers for the sequence of DH501 unmutated
common ancestor heavy and light chain reported in this paper are GenBank:
KY490542 and KY490543.
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